A fractional executive provides senior-level portfolio governance and execution leadership typically delivered by a full-time C-suite leader (such as a Head of PMO or Portfolio Strategy), but on a structured part-time or engagement basis. This enables organizations to access 25+ years of regulated biotech leadership and PfMP®/PMP® expertise without expanding permanent executive overhead.

Growth-stage biotech, MedTech, and regulated life sciences companies managing IND, NDA, GMP, or multi-CRO execution environments benefit most from structured portfolio discipline and capital protection frameworks.

Fractional governance installs escalation controls, portfolio visibility, and disciplined decision architecture that typically improves operational efficiency by 7–10% within the first engagement cycle.

Engagements are structured to match portfolio complexity and stakeholder needs. Most advisory and governance work is delivered remotely to maintain velocity and cost efficiency, with on-site sessions incorporated for executive alignment, board preparation, or critical escalation points. Hybrid structures are common in regulated biotech and multi-CRO environments. The model prioritizes decision clarity and measurable capital impact, not physical presence.

Ongoing insights are shared through the Ignite Accelerator executive briefings and periodic video briefings focused on biotech portfolio governance, execution discipline, and AI-enabled operational control. These briefings translate field-tested governance frameworks into practical executive action. Selected content is also available through LinkedIn and curated executive summaries. You can explore detailed execution architecture and capital impact in the Execution & Impact overview.

All engagements are governed by formal confidentiality agreements and structured access controls aligned with regulated life sciences standards. Portfolio data, clinical milestones, and vendor performance metrics are reviewed within clearly defined governance boundaries. AI-enabled reporting workflows, where used, operate within secure enterprise environments and never replace human regulatory judgment. Confidentiality, audit integrity, and capital protection remain non-negotiable.

Multi-vendor biotech environments often suffer from fragmented reporting and delayed escalation signals. Governance frameworks unify milestone tracking, risk visibility, and decision accountability across CROs and CDMOs. The objective is early signal detection before timeline erosion becomes financial loss. Alignment reduces decision latency and protects development capital without adding bureaucracy.

AI-enabled governance reduces manual reporting burden, surfaces risk patterns earlier, and improves decision velocity across portfolio environments. Savings typically come from reduced redundant effort, fewer escalation delays, and clearer capital prioritization — not automation hype. When structured correctly, AI augments portfolio visibility while preserving compliance oversight. The measurable impact is improved operational efficiency within the first engagement cycle.

AI is applied selectively within analytics, reporting synthesis, and risk pattern detection — never within regulatory judgment or quality authority functions. Governance architecture defines where AI augments leadership and where human oversight remains mandatory. Structured guardrails ensure audit traceability and documentation integrity. The result is improved velocity without regulatory exposure.

Runway erosion is typically driven by capital misallocation, delayed escalation, and portfolio drift rather than scientific failure alone. Structured governance improves milestone clarity, decision cadence, and capital prioritization. This reduces rework, compresses delays, and strengthens cross-functional alignment. Measurable efficiency gains often emerge within the first operating cycle.

Advisory engagements focus on installing governance architecture, portfolio discipline, and executive decision frameworks while internal leaders execute. Interim leadership mandates include direct operational oversight of PMO, portfolio, or multi-CRO environments during transition or stabilization periods. Both models are structured for measurable capital impact. The choice depends on organizational maturity and execution risk exposure.

Engagements typically range from 10–50 hours per month depending on portfolio complexity, regulatory exposure, and capital sensitivity. Fractional structures allow senior-level oversight without expanding permanent executive overhead. Capacity is intentionally selective to ensure focus and measurable impact. Hybrid delivery models are common in regulated biotech environments.

Fees are structured around scope, portfolio risk profile, and expected capital impact rather than hourly billing. Engagements are designed so verified operational and efficiency gains materially exceed advisory investment. Clear deliverables, milestone checkpoints, and governance objectives are defined at the outset. Transparency and measurable ROI are core principles.

For a structured engagement discussion, see the Contact page.

Integration typically begins within weeks following alignment on scope and governance priorities. Initial engagement focuses on portfolio visibility, risk mapping, and decision architecture assessment. Early wins are prioritized to stabilize execution before broader transformation. The objective is rapid clarity without disrupting ongoing scientific momentum.